Skip to content

How to keep muscle while losing weight on Ozempic or Mounjaro

A big slice of GLP-1 weight loss is lean mass, not just fat. Two simple habits protect your strength, and the trial numbers are far less scary than the headlines.

Updated · 13 min read

The short answer

Yes, some of it is muscle: roughly 25 to 40% of the weight you lose on Ozempic, Wegovy or Mounjaro (Zepbound in the US) is lean mass, not fat. Two habits help prevent it: lift weights two to three times a week and eat about 1.2 to 1.5 g of protein per kg of body weight per day. The numbers are less alarming than the headlines. "Lean mass" on a DXA body scan also counts water, glycogen and organ tissue. And in studies, body composition often improved while grip strength held steady. What matters is tracking strength and function, not just the scale.

This content is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making changes to your diet, exercise routine, or supplement regimen.

How much muscle do you actually lose on Ozempic or Mounjaro?

Roughly a quarter to 40% of the weight you drop on a GLP-1 is lean mass (the fat-free stuff), not fat. Sounds alarming. The detail matters way more than that headline number, so stick with me.

Start with the trials. In the STEP 1 substudy, people took semaglutide 2.4 mg and got scanned with DXA (a body scan that splits you into fat, lean tissue and bone). They lost a lot of fat: total fat mass fell 19.3% and belly fat 27.4% over 68 weeks. Lean mass dropped 9.7%. Do the math and lean mass was close to 40% of all the weight they lost [1]. Tirzepatide looked gentler. In the SURMOUNT-1 substudy, fat mass fell 33.9% (about 15.9 kg) and lean mass 10.9% (about 5.6 kg) over 72 weeks. So roughly 74 to 75% of the loss was fat, and 25 to 26% was lean [2].

Trial Drug Weeks Lean mass change Lean share of weight lost
STEP 1 [1] Semaglutide 2.4 mg 68 -9.7% about 40%
SURMOUNT-1 [2] Tirzepatide 72 -10.9% about 25 to 26%
BELIEVE [7] Semaglutide alone 72 -7.4% about 24%
BELIEVE [7] Bimagrumab + semaglutide 72 -2.9% about 8%

Different trials, different people and scans, so read this as a range, not a head-to-head ranking. The bimagrumab combo is not approved yet. More on it in the last section.

Now the part the scary headlines skip. "Lean" or "fat-free" mass on a DXA scan is not the same thing as muscle. It also counts water, glycogen (your stored carbs), bone and organ tissue. So those lean-loss kilos overstate how much actual muscle you lose. Do not treat the two as equal.

It gets better. Your overall body shape can improve even while raw lean mass drops. In STEP 1, lean mass as a share of total body weight went up 3.0 percentage points [1]. The lean-to-fat ratio got better too, even more so in people who lost at least 15% of their weight [1]. Tirzepatide took off far more fat than lean, so its body-composition shift looked even better [2].

One last bit of reassurance. In SURMOUNT-1, that 25% lean slice of the weight lost was basically the same in the placebo group [2]. In plain terms: GLP-1s are not unusually catabolic (muscle-wasting). Some lean loss rides along with almost any fast weight loss, whether it comes from dieting, surgery or these drugs. What really matters is how much and how fast, especially once you are older. (For the bigger picture on why these drugs matter beyond the scale, see our guide on GLP-1 and longevity.)

Since July 2026, semaglutide is also approved in the EU as a Wegovy pill. For your muscles nothing changes: same drug, same rules for lifting and protein.

Is losing muscle on a GLP-1 actually a problem?

Some lean-mass loss is normal, expected, and not automatically a bad thing. The fat you drop buys you real metabolic payoff. What matters for your future is muscle function and strength, not one number on a DXA report.

Why split those hairs? Because strength and mass do not move together in the short term. In the SEMALEAN study, people on semaglutide lost about 3.0 kg of lean mass by month 7, then held steady through month 12. And yet their handgrip strength went up by 4.1 kg [8]. The share of people with sarcopenic obesity (low muscle plus high fat at the same time) dropped from 49% to 33% [8]. They got lighter, lost a little lean tissue on paper, and got stronger. That is exactly the pattern you want.

There is a flip side, though. In older adults with type 2 diabetes, longer-term semaglutide use has been linked to weaker grip and faster sarcopenia [9]. That same work drives home a key point: lean-mass loss does not reliably tell you what strength will do. A DXA number cannot tell you whether your function got better or worse.

So who should be most careful?

  • Older adults, whose muscle reserve is already thinner.
  • Frail people, or anyone with sarcopenia risk before they even start.
  • People losing weight fast, since speed and size of the loss crank up the worry.

Keep bone on the watch list too, since rapid weight loss can hit it.

The message is not "stay away from these drugs." It is that the scale and the DXA printout cannot tell you whether you are getting frailer or fitter. Strength can. If you are 40-plus, and especially 65-plus, strength and function are the real things to protect. The next two sections show you how. (If you are a man over 40, our longevity guide for men 40+ puts muscle in the wider picture.)

How to prevent muscle loss on a GLP-1: Which exercise works?

Lift weights two to three times a week. That is the single best-proven way to hold onto muscle while you lose weight. Strength training does three things at once: it protects fat-free mass, it tips more of the loss toward fat, and it makes you noticeably stronger.

The headline number comes from a 2025 meta-analysis (a study that pools many trials into one big result) covering 25 randomised trials and 1,608 people [4]. It pitted strength training during weight loss against dieting alone, and the picture was mostly positive. The researchers report each result as a standardised effect, which is just a way to compare studies on one scale:

  • Fat-free mass: +0.40 (95% CI 0.18 to 0.61), so more lean mass kept. The CI, or confidence interval, is the range the true effect most likely sits in.
  • Fat mass: -0.36 (95% CI -0.49 to -0.23), so more fat lost.
  • Strength: +2.36, a big jump in how strong people got.

That is a rare three-for-one: keep more lean mass, lose more fat, get stronger, all off the same habit. Two footnotes. These trials were in adults aged 18 to 65, and the lean-mass effect was clear in programs up to about 5 months but not statistically clear in longer ones. The strength result is big but rated low certainty [4].

Studies in older people on calorie-cut diets point the same way: a 2018 meta-analysis [10] and a 2017 NEJM trial in dieting older adults with obesity [13]. In that trial, lean mass still dipped a little with lifting, just less than with cardio alone. Lifting plus cardio improved day-to-day function the most [13].

One catch changes how you read all of this. None of these trials bolted strength training specifically onto semaglutide or tirzepatide. The evidence comes from diet-based and general weight-loss studies. The biology is the same and the advice is sound, but a big GLP-1-specific exercise trial has not reported yet. So treat this as the best evidence we have, with solid biology behind it, not as proven for people on these exact drugs.

So what do you actually do? Keep it boring and repeatable.

  1. Two to three full-body strength sessions a week [10, 11]. That is the dose the data backs, not five.
  2. Hit the big movements: a squat or leg press, a push (like a push-up or press), a pull (like a row), and a hinge (bending at the hips, like a deadlift).
  3. Add a bit of weight or one more rep when a set starts to feel easy. Progression is the active ingredient.
  4. Skip the fancy gym. Bands, dumbbells, or your own bodyweight all count if you make them hard enough.

Walking is great for your heart, but on its own it will not keep your muscle. Here, the lifting is the part that protects you. (Aerobic work still earns its place for your heart and stamina, which is what Zone 2 and VO2max training are for.)

How much protein should you eat on a GLP-1, and why is it so hard?

Eat more protein than you used to, especially while the weight is actively coming off. The practical target for older adults and anyone at risk is roughly 1.2 to 1.5 g of protein per kg of body weight per day. In weight-loss practice the aim often sits near the top of that band (around 1.5 g/kg of your target weight) [11].

Where do those numbers come from? Two big consensus papers, both relevant here in DACH: the PROT-AGE position paper [5] and the ESPEN expert group [6]. They set 1.0 to 1.2 g/kg/day as the baseline for a healthy older adult, then bump it to 1.2 to 1.5 g/kg when someone is ill or at risk. One caveat: these targets were written for aging and general weight loss, then carried over to GLP-1 users. Nobody has tested them head-to-head in semaglutide or tirzepatide trials.

One exception: if you have serious kidney disease (an eGFR, your kidney filtering score, under 30) and are not on dialysis, do not raise protein on your own. Ask your doctor first [5]. And if you carry a lot of extra weight, base the grams on your target weight, not your current weight [11].

How you eat protein matters as much as how much. The consensus advice is to spread it out. Aim for about 25 to 30 g of good-quality protein per meal across the day, and pair it with your lifting. Protein plus strength training beats either one alone for holding muscle. Higher-protein, energy-restricted diets also help protect fat-free mass while you lose weight [14].

The real-world snag: GLP-1 drugs work by dampening your appetite. That is the whole point. But it also makes a protein target genuinely hard to hit, because three small bites in and you feel full. Protein will not happen by accident on these drugs. You have to build meals around it on purpose.

A few moves that work:

  • Eat the protein first, before the carbs and veg, while your appetite still plays along.
  • Load it earlier in the day, when nausea tends to be milder.
  • Keep easy options ready: skyr, Magerquark (low-fat quark), eggs, tuna, a protein shake.
  • If a full meal feels impossible, a 25 g protein snack still counts toward the daily total.

Think of protein as the food job and lifting as the movement job. Together they are what keep the weight you lose mostly fat. Not sure what your gram target is? Work it out with our protein calculator. For your maintenance calories, our free calorie calculator uses your height, weight and activity.

How do you track whether you are keeping muscle, not just losing weight?

Track strength and function, not just the number on the scale. Our rule of thumb: "Funktion vor Waage," function before the scale. The win is a lighter and stronger you. The bathroom scale cannot tell you whether you are getting stronger or weaker.

Why not just weigh yourself? Because the scale dumps fat, muscle, water and food into one number. You can lose 8 kg and be fitter, or lose 8 kg and be frailer, and the scale reads the same either way. Strength and function are what tell the two apart.

In DACH, the useful tools are cheap and easy to find.

  • Handgrip dynamometry. A simple squeeze test, available in many practices and gyms, that tracks your overall strength surprisingly well. SEMALEAN used exactly this measure [8]. You can benchmark your own reading by age and sex with our grip strength calculator.
  • Bioimpedance (BIA). Those body-composition scales you find in many gyms and pharmacies that send a tiny current through you to estimate muscle and fat. Less precise than DXA, but fine for following your own trend over months.
  • Chair-stand test. Stand up from a chair and sit back down as many times as you can in 30 seconds, or time five reps. Free, repeatable at home, and a solid stand-in for leg strength and function.

DXA gives the most precise body-composition read, splitting you into fat, lean and bone. The catch in DACH is access and cost: DXA for body composition is harder to get and usually self-pay. A baseline scan plus one follow-up gives you a clean before-and-after, but you do not need it to monitor well.

The trick is to watch the trend over months, not single snapshots. Short-term DXA lean numbers can overstate the real-world harm, since strength often holds or even climbs while lean mass dips, just like SEMALEAN showed [8]. And in older adults with type 2 diabetes, longer-term data point to strength loss that a DXA lean number may not show [9]. So pick one strength test and one function test, retest every couple of months, and trust the direction of the line. If your grip and chair-stand hold steady or improve while the weight drops, you are doing this right.

Is there a weight-loss drug without muscle loss yet?

Yes, a muscle-sparing combo is in the pipeline, and the early data look striking. No, you cannot get it yet. The drug is bimagrumab, an antibody that releases one of the body's brakes on muscle growth (it blocks the activin type II receptor). Researchers tested it alongside semaglutide in the phase 2 BELIEVE trial, with 507 participants.

Here is the result that turned heads. High-dose bimagrumab plus semaglutide produced about 22% weight loss by week 72, and around 92% of that weight loss came from fat. The main readout at week 48 already put the combo ahead of semaglutide alone. Weeks 48 to 72 were an open-label extension, meaning people knew what they were taking. Total lean mass barely moved: it fell only about 2.9% from baseline. Semaglutide on its own in the same trial managed about 15.7% weight loss, of which roughly 75.6% was fat, and its total lean mass fell about 7.4% from baseline [7]. So the combo lost more weight and held onto far more lean mass.

Now ease off the gas. BELIEVE is phase 2 and still investigational. Bimagrumab is not approved, not standard care, and it carries its own side-effect profile (muscle spasms, diarrhea and acne were common) that trials are still mapping out [7]. Treat it as a promising future option, not something to ask for next month.

For now, your real-world levers in DACH are still the same three: lifting, protein, monitoring. And for most people the drug itself is a self-pay cost.

In Germany, Wegovy (semaglutide) and Mounjaro (tirzepatide) for weight loss are not reimbursed. They count as Lifestyle-Arzneimittel (lifestyle drugs) under § 34 Abs. 1 SGB V, so statutory insurance (GKV) will not pay. You need a Privatrezept (private prescription) and you pay yourself. Rough 2026 self-pay prices:

  • Wegovy: about EUR 173 to 278 per month up to the 2.4 mg maintenance dose, and a dedicated 7.2 mg pen was approved in the EU in July 2026, but no German price was listed as of September 2026.
  • Mounjaro: about EUR 206 to 482 per month, depending on dose.

Statutory insurance does pay when the drug is prescribed for type 2 diabetes, such as Ozempic, or Mounjaro in its diabetes use.

Switzerland is different: basic insurance can pay for Wegovy if your BMI is 35 or more (or 28 or more with conditions like prediabetes, high blood pressure or high blood lipids), a qualified specialist or obesity centre starts it, and you hit set weight-loss targets. Cover stops after 3 years at most [16]. For Mounjaro, cover for weight loss without type 2 diabetes is much more restrictive, so ask your insurer first. Wegovy's Swiss listing is temporary (currently until 28 February 2027), so check the current status. In Austria, plan on paying yourself for the weight-loss use.

One word of caution on the prices. They depend on dose, they bounce around, and supply has been patchy. These figures come from pharmacy price lists, so check a current Lauer-Taxe price (the official German drug price list) or a pharmacy quote before you budget on any one number. Full prices, doses and insurance rules are in our weight-loss jab cost guide.

Frequently asked questions

How do I prevent muscle loss on Ozempic or Mounjaro?

Use three levers. Lift two to three times a week with full-body sessions [10, 11]. A meta-analysis of 25 trials found lifting during weight loss keeps more fat-free mass [4]. Eat about 1.2 to 1.5 g of protein per kg per day, split into 25 to 30 g per meal [5, 6]. If you have serious kidney disease, ask your doctor before raising protein [5]. And retest grip strength and a chair-stand every few months instead of trusting the scale. In SEMALEAN, grip rose even as lean mass dipped [8].

How much of the weight you lose on Ozempic is muscle?

On semaglutide in the STEP 1 substudy, lean mass fell 9.7%, close to 40% of the total weight lost [1]. On tirzepatide in SURMOUNT-1 it was about 25 to 26% [2]. But DXA lean mass counts water, glycogen and organ tissue too, not just muscle, so the real muscle loss is smaller than that figure makes it sound. Body composition still got better overall, because lean mass rose 3.0 points as a share of body weight [1].

Is muscle loss a side effect of Ozempic or Mounjaro?

Not in the usual sense. Some lean mass goes with almost any fast weight loss, whether from dieting, surgery or a GLP-1. In SURMOUNT-1, the lean share of weight lost on tirzepatide, about 25%, was basically the same as on placebo [2]. The group to watch is older adults, where longer-term semaglutide use in type 2 diabetes has been linked to weaker grip [9].

Will I get sarcopenia (muscle wasting) from taking a GLP-1?

Not automatically. Some lean-mass loss rides along with any fast weight loss, and in SEMALEAN sarcopenic obesity actually fell from 49% to 33% while grip strength improved [8]. The higher-risk group is older adults, especially with type 2 diabetes, where longer-term use has been linked to weaker grip [9]. Strength training and enough protein are your main protection.

Do I need to lift weights on Mounjaro or Wegovy?

It is the single most effective thing you can do for muscle. A 2025 meta-analysis of 25 trials with 1,608 people found strength training during weight loss keeps fat-free mass, boosts fat loss, and raises strength a lot, though the strength result is rated low certainty [4]. The dose that works is two to three full-body sessions a week [10, 11]. Walking helps your heart but will not keep your muscle on its own.

Can you build muscle on Mounjaro?

You can build strength, but adding much muscle mass in a calorie deficit is unlikely. In SEMALEAN, handgrip rose 4.1 kg on semaglutide even as lean mass dipped [8]. A meta-analysis of 25 trials found lifting during weight loss keeps more fat-free mass and makes people stronger [4]. So the realistic goal is to keep muscle and get stronger, not to bulk up.

How much protein should I eat while on a GLP-1?

Aim for roughly 1.2 to 1.5 g per kg of body weight per day if you are older or at risk, based on the PROT-AGE and ESPEN guidelines [5, 6]. If you carry a lot of extra weight, use your target weight for the math [11]. Spread it across meals at about 25 to 30 g of good-quality protein each. The hard part is the dampened appetite, so eat protein first and keep easy options like quark, skyr and eggs on hand. With serious kidney disease, ask your doctor first [5].

Do protein shakes help on a GLP-1?

Yes, as a tool, not a must. With your appetite dialed down, a shake is often the easiest way to get 25 to 30 g of protein into one sitting. The daily target for older or at-risk adults is about 1.2 to 1.5 g per kg of body weight [5, 6], and higher-protein diets help protect fat-free mass while you lose weight [14]. Skyr, quark or eggs work just as well.

Is there a weight-loss drug that doesn't cause muscle loss?

Not yet, but one is in trials. Bimagrumab plus semaglutide in the phase 2 BELIEVE trial reached about 22% weight loss by week 72. Roughly 92% of it was fat, and total lean mass fell only about 2.9% from baseline [7]. It is investigational, not approved, and carries side-effect signals, so it is a future option rather than care you can get today.

Does losing muscle on semaglutide make me weaker?

Not necessarily, at least short term. In SEMALEAN, handgrip strength improved by 4.1 kg even as lean mass fell [8]. Lean-mass loss does not reliably predict what strength will do. But in older adults with type 2 diabetes, longer-term use has been linked to weaker grip [9], which is why tracking strength matters most as you age.

How can I check if I'm losing muscle instead of fat?

Track strength and function, not just the scale. Handgrip dynamometry and bioimpedance (BIA) are cheap and easy to find in DACH gyms and practices, and a 30-second chair-stand test is a free home stand-in. DXA is the most precise but usually self-pay. Watch the trend over months: if your grip and chair-stand hold steady or improve while the weight drops, you are keeping muscle.

Sources

  1. Wilding JPH, Batterham RL, Calanna S, Van Gaal LF, McGowan BM, Rosenstock J, Tran MTD, Wharton S, Yokote K, Zeuthen N, Kushner RF. (2021). Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Societydoi:10.1210/jendso/bvab048.030
  2. Look M, Dunn JP, Kushner RF, Cao D, Harris C, Hunter Gibble T, Stefanski A, Griffin R. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolismdoi:10.1111/dom.16275
  3. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicinedoi:10.1056/NEJMoa2206038
  4. Binmahfoz A, Dighriri A, Gray C, Gray SR. (2025). Effect of resistance exercise on body composition, muscle strength and cardiometabolic health during dietary weight loss in people living with overweight or obesity: a systematic review and meta-analysis. BMJ Open Sport & Exercise Medicinedoi:10.1136/bmjsem-2024-002363
  5. Bauer J, Biolo G, Cederholm T, Cesari M, Cruz-Jentoft AJ, Morley JE, Phillips S, Sieber C, Stehle P, Teta D, Visvanathan R, Volpi E, Boirie Y. (2013). Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. Journal of the American Medical Directors Association (JAMDA)doi:10.1016/j.jamda.2013.05.021
  6. Deutz NEP, Bauer JM, Barazzoni R, Biolo G, Boirie Y, Bosy-Westphal A, Cederholm T, Cruz-Jentoft A, Krznaric Z, Nair KS, Singer P, Teta D, Tipton K, Calder PC. (2014). Protein intake and exercise for optimal muscle function with aging: Recommendations from the ESPEN Expert Group. Clinical Nutritiondoi:10.1016/j.clnu.2014.04.007
  7. Heymsfield SB, Aronne LJ, et al. (2026). Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial (BELIEVE). Nature Medicinedoi:10.1038/s41591-026-04204-0
  8. Alissou M, Demangeat T, Folope V, et al. (2025). Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes, Obesity and Metabolismdoi:10.1111/dom.70141
  9. Prokopidis K. (2026). Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions. British Journal of Pharmacologydoi:10.1111/bph.70355
  10. Sardeli AV, Komatsu TR, Mori MA, Gáspari AF, Chacon-Mikahil MPT. (2018). Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis. Nutrientsdoi:10.3390/nu10040423
  11. Mechanick JI, Butsch WS, Christensen SM, et al. (2025). Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obesity Reviewsdoi:10.1111/obr.13841
  12. Tinsley GM, Nadolsky S. (2025). Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. SAGE Open Medical Case Reportsdoi:10.1177/2050313X251388724
  13. Villareal DT, Aguirre L, Gurney AB, et al. (2017). Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults. New England Journal of Medicinedoi:10.1056/NEJMoa1616338
  14. Wycherley TP, Moran LJ, Clifton PM, Noakes M, Brinkworth GD. (2012). Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials. American Journal of Clinical Nutritiondoi:10.3945/ajcn.112.044321
  15. Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. (2024). Muscle matters: the effects of medically induced weight loss on skeletal muscle. The Lancet Diabetes & Endocrinologydoi:10.1016/S2213-8587(24)00272-9
  16. Gerber PA, Collet TH, Favre L, Bueter M, Ruiz Arana I, Durrer D, Seelig E, Schultes B, Pasi P, Konrad D, Bally L. (2026). Swiss obesity clinical practice guidance. Swiss Medical Weeklydoi:10.57187/5415

Losing weight on a GLP-1? Keep your strength alongside you.

Join Longevity Austria to swap protein-first meal ideas, strength routines that fit a busy week, and honest experiences from others on semaglutide or tirzepatide across Germany, Austria and Switzerland.

Join the community

Experts in this field

Speakers from the Longevity Austria community on this topic

Related guides

Created by Maurice Lichtenberg, Founder, Longevity Cities

The information provided here is for educational purposes only. Longevity Austria does not provide medical advice, diagnosis, or treatment. Always seek the advice of qualified healthcare providers with questions regarding medical conditions.